301087.SHE Cofoe Medical Technology Co.Ltd.
- Market cap
- CNY 11.9B
- P/E
- 26.1x
- P/B
- 2.16x
- ROE
- 7.3%
- Dividend yield
- 3.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 301087.SHE undervalued?
Graham number301087.SHE trades 58.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cofoe Medical Technology Co.Ltd. fundamental analysis
No fundamental analysis for Cofoe Medical Technology Co.Ltd. yet.
Cofoe Medical Technology Co.Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cofoe Medical Technology Co.Ltd.
Cofoe Medical Technology Co.,Ltd. engages in the research and development, production, sales, and service of home care medical devices in China. The company offers medical and wellness products for various types of diseases treatment, damage therapy, daily health maintenance, and life quality improvement. It also offers rehabilitation aids products, such as hearing aids, electric wheelchair, and orthopedic/posture correction products; medical care products, such as dressing …
Full company profileCofoe Medical Technology Co.Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cofoe Medical Technology Co.Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.46B | 2.38B | 2.28B | 2.98B | 2.85B | 2.98B | 3.39B | 4.14B |
| Gross Profit | 561M | 1.02B | 997M | 1.18B | 1.24B | 1.55B | 1.80B | 2.32B |
| Operating Income | 170M | 527M | 527M | 329M | 278M | 362M | 396M | 516M |
| EBITDA | 185M | 522M | 580M | 445M | 435M | 552M | 626M | 507M |
| Net Income | 124M | 424M | 429M | 302M | 254M | 312M | 372M | 405M |
| EPS | 0.79 | 2.72 | 2.06 | 1.45 | 1.22 | 1.49 | 1.78 | 1.71 |
| Balance Sheet | ||||||||
| Total Assets | 1.05B | 1.87B | 5.81B | 6.41B | 6.24B | 6.42B | 6.63B | 7.46B |
| Total Liabilities | 450M | 872M | 842M | 1.38B | 1.34B | 1.62B | 1.73B | 1.89B |
| Shareholders' Equity | 596M | 992M | 4.95B | 5.02B | 4.90B | 4.80B | 4.87B | 5.53B |
| Cash & Short-term Investments | 369M | 557M | 1.99B | 1.45B | 1.57B | 1.28B | 1.42B | 2.48B |
| Cash Flow | ||||||||
| Operating Cash Flow | 57.4M | 496M | 240M | 98.9M | 394M | 663M | 696M | - |
| Capital Expenditure | 105M | 374M | 513M | 640M | 373M | 120M | 178M | 163M |
| Free Cash Flow | -48.0M | 122M | -273M | -541M | 20.6M | 543M | 518M | 362M |
| Ratios | ||||||||
| ROE | 20.7% | 42.8% | 8.7% | 6.0% | 5.2% | 6.5% | 7.6% | 7.3% |
| ROA | 11.8% | 22.7% | 7.4% | 4.7% | 4.1% | 4.9% | 5.6% | 5.4% |
| Net Profit Margin | 8.5% | 17.8% | 18.8% | 10.1% | 8.9% | 10.5% | 11.0% | 9.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cofoe Medical Technology Co.Ltd. dividends
- Dividend yield
- 3.11%
- Forward dividend
- 1.80 CNY
- Payout ratio
- 100.0%
- Ex-dividend date
- Sep 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 372M | 1.78 | 100.0% |
| 2024 | CNY 374M | 1.79 | 120.1% |
| 2023 | CNY 250M | 1.19 | 98.3% |
| 2022 | CNY 260M | 1.25 | 86.0% |
| 2021 | CNY 2.70M | 0.01 | 0.6% |
| 2020 | CNY 32.7M | 0.21 | 7.7% |
| 2019 | CNY 5.50M | 0.04 | 4.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on May 20, 2022.
Who owns Cofoe Medical Technology Co.Ltd.
- Insiders 57.71%
- Institutions 9.41%
- Public & others 32.88%
- Shares outstanding 209M
- Free float 103M
Cofoe Medical Technology Co.Ltd. company profile
- Company name
- Cofoe Medical Technology Co.Ltd.
- Ticker
- 301087.SHE
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 5,081
- Fiscal year end
- December
- Address
- No. 87, Changsha, China, 410000
- Phone
- 86 40 0888 6170
- Website
- cofoe.com.cn
About Cofoe Medical Technology Co.Ltd.
Cofoe Medical Technology Co.,Ltd. engages in the research and development, production, sales, and service of home care medical devices in China. The company offers medical and wellness products for various types of diseases treatment, damage therapy, daily health maintenance, and life quality improvement. It also offers rehabilitation aids products, such as hearing aids, electric wheelchair, and orthopedic/posture correction products; medical care products, such as dressing products and ostomy care products; health monitoring products for monitoring human physiological parameters including metabolic disease testing product and thermometers; respiratory support products including non-invasive ventilators and nebulizers; and TCM therapy and other products, such as physiotherapy devices. Additionally, the company offers logistics and warehousing services to third party medical product companies and on-line storemanagement services. Further, the company manufactures its products through the Original Design Model, through which, it collaborates with customers to develop designs of products itmanufactures; and the original equipment manufacturing model, through which its customers provide their designs and it manufactures. The company sells its products through both offline and online channels comprising direct sales primarily via self-owned and online stores, sales to third party pharmacy chain operators, sales to offline and online distributors, and through e-commerce platforms. It sells its products through its brands Cofoe, JOYOR HearingCare, Jerry Medical, Huazhou, and babaka. The company was formerly known as Hunan Cofoe Medical Technology Development Co., Ltd. and changed its name to Cofoe Medical Technology Co.,Ltd. in December 2026. Cofoe Medical Technology Co.,Ltd. was founded in 2005 and is headquartered in Changsha, China.
Cofoe Medical Technology Co.Ltd. management
10- Mr. Min ZhangChairman of the Board & President · born 1979
- Mr. Zhiming ZhangExecutive Vice Chairman · born 1979
- Mr. Wangpeng ChenVP & CFO · born 1980
- Mr. Bangjie HeExecutive Director · born 1979
- Mr. Xiaoqiao XueVP, Board Secretary & Executive Director · born 1980
- Mr. Hanqing ZuoVice President · born 1990
- Mr. Jie OuyangVice President · born 1983
- Mr. Xiangyu YuVice President · born 1981
- Pei ShenHead of Accounting Department
- Ms. Ching Ching HaJoint Company Secretary · born 1979